Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18196842 | 0.99 | ALDH1A1 (0.65) | POLBALDH1A1KEAP1NFE2L2CHRM3 | |
| SCHEMBL20253541 | 0.91 | ALDH1A1 (0.62) | POLBALDH1A1KEAP1NFE2L2CHRM3 | |
| SCHEMBL25134509 | 0.85 | KEAP1 (0.60) | POLBALDH1A1KEAP1NFE2L2CHRM3 | |
| SCHEMBL3042271 | 0.79 | POLB (0.47) | POLBALDH1A1KEAP1NFE2L2CHRM3 | |
| SCHEMBL5133653 | 0.78 | ALDH1A1 (0.48) | POLBALDH1A1KEAP1NFE2L2CHRM3 | |
| SCHEMBL4878955 | 0.78 | ALDH1A1 (0.62) | POLBALDH1A1KEAP1NFE2L2CHRM3 | |
| SCHEMBL4914500 | 0.77 | KEAP1 (0.51) | POLBALDH1A1KEAP1NFE2L2CHRM3 | |
| SCHEMBL3053693 | 0.77 | ALDH1A1 (0.47) | POLBALDH1A1KEAP1NFE2L2CHRM3 | |
| SCHEMBL3034644 | 0.77 | POLB (0.45) | POLBALDH1A1KEAP1NFE2L2CHRM3 | |
| SCHEMBL5134240 | 0.77 | ALDH1A1 (0.47) | POLBALDH1A1KEAP1NFE2L2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307355-B2 | N-aralkylcarbonyldiamine compounds and personal care compositions comprising the same | CONOPCO, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180161260-A1 | N-ARALKYLCARBONYLDIAMINE COMPOUNDS AND PERSONAL CARE COMPOSITIONS COMPRISING THE SAME | CONOPCO, INC., D/B/A UNILEVER (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180161260-A1 | N-ARALKYLCARBONYLDIAMINE COMPOUNDS AND PERSONAL CARE COMPOSITIONS COMPRISING THE SAME | CONOPCO, INC., D/B/A UNILEVER (US) | 2018-06-14 | — | — | US | disclosed |
| WO-2016173818-A1 | N-ARALKYLCARBONYLDIAMINE COMPOUNDS AND PERSONAL CARE COMPOSITIONS COMPRISING THE SAME | UNILEVER PLC (GB) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10307355-B2 | N-aralkylcarbonyldiamine compounds and personal care compositions comprising the same | CUTA, AAAS, ACMSD | POLB 1538/4885ALDH1A1 2552/4885KEAP1 253/4885 |
| US-20180161260-A1 | N-ARALKYLCARBONYLDIAMINE COMPOUNDS AND PERSONAL CARE COMPOSITIONS COMPRISING THE SAME | CUTA, ACMSD, KRT18 | POLB 878/4885ALDH1A1 2412/4885KEAP1 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.